These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 19722915)

  • 1. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations.
    Hamza Yel-S; Aburahma MH
    Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel sustained-release fast-disintegrating multi-unit compressed tablets of lornoxicam containing Eudragit RS coated chitosan-alginate beads.
    Aburahma MH; Hamza Yel-S
    Pharm Dev Technol; 2011 Aug; 16(4):316-30. PubMed ID: 20307250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and in vitro evaluation of novel sustained- release matrix tablets for lornoxicam based on the combination of hydrophilic matrix formers and basic pH-modifiers.
    Hamza Yel-S; Aburahma MH
    Pharm Dev Technol; 2010; 15(2):139-53. PubMed ID: 19895367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and in vitro evaluation of novel sustained-release double-layer tablets of lornoxicam: utility of cyclodextrin and xanthan gum combination.
    Hamza Yel-S; Aburahma MH
    AAPS PharmSciTech; 2009; 10(4):1357-67. PubMed ID: 19921543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissolution enhancement and formulation of rapid-release lornoxicam mini-tablets.
    Tawfeek HM; Saleem IY; Roberts M
    J Pharm Sci; 2014 Aug; 103(8):2470-83. PubMed ID: 24995853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study on the in vitro performance of blister molded and conventional lornoxicam immediate release liquitablets: accelerated stability study and anti-inflammatory and ulcerogenic effects.
    El-Setouhy DA; Gamiel AA; Badawi AA; Osman AS; Labib DA
    Pharm Dev Technol; 2017 Mar; 22(2):256-265. PubMed ID: 27494155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
    Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
    Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Biodegradable Injectable In situ Forming Implants for Sustained Release of Lornoxicam.
    Christian R; Thakkar V; Patel T; Gohel M; Baldaniya L; Shah P; Pandya T; Gandhi T
    Curr Drug Deliv; 2019; 16(1):66-78. PubMed ID: 30264681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and evaluation of sustained-release Compritol® 888 ATO matrix mini-tablets.
    Roberts M; Vellucci D; Mostafa S; Miolane C; Marchaud D
    Drug Dev Ind Pharm; 2012 Sep; 38(9):1068-76. PubMed ID: 22149472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
    Maghsoodi M; Sadeghpoor F
    Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of hydroxypropyl-beta-cyclodextrin complexation on piroxicam release from buccoadhesive tablets.
    Jug M; Bećirević-Laćan M
    Eur J Pharm Sci; 2004 Feb; 21(2-3):251-60. PubMed ID: 14757497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and pharmacokinetics evaluation of oral self-emulsifying system for poorly water-soluble drug Lornoxicam.
    Li F; Song S; Guo Y; Zhao Q; Zhang X; Pan W; Yang X
    Drug Deliv; 2015; 22(4):487-98. PubMed ID: 24524289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study.
    Teaima MH; Abdel-Haleem KM; Osama R; El-Nabarawi MA; Elnahas OS
    Drug Des Devel Ther; 2021; 15():4229-4242. PubMed ID: 34675486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble filler as a dissolution profile modulator for slightly soluble drugs in matrix tablets.
    Dvorácková K; Rabisková M; Masteiková R; Muselík J; Krejcová K
    Drug Dev Ind Pharm; 2009 Aug; 35(8):930-40. PubMed ID: 19274510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmaceutical study on lornoxicam fast disintegrating tablets: formulation and in vitro and in vivo evaluation.
    Moutasim MY; ElMeshad AN; El-Nabarawi MA
    Drug Deliv Transl Res; 2017 Jun; 7(3):450-459. PubMed ID: 28283842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation and evaluation of mini-tablets-filled-pulsincap delivery of lornoxicam in the chronotherapeutic treatment of rheumatoid arthritis.
    Hadi MA; Rao NG; Rao AS
    Pak J Pharm Sci; 2015 Jan; 28(1):185-93. PubMed ID: 25553695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of excipients, drugs, and osmotic agent in the inner core on the time-controlled disintegration of compression-coated ethylcellulose tablets.
    Lin SY; Lin KH; Li MJ
    J Pharm Sci; 2002 Sep; 91(9):2040-6. PubMed ID: 12210050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of two polymorphs of lornoxicam.
    Zhang J; Tan X; Gao J; Fan W; Gao Y; Qian S
    J Pharm Pharmacol; 2013 Jan; 65(1):44-52. PubMed ID: 23215687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations.
    Kranz H; Wagner T
    Eur J Pharm Biopharm; 2006 Jan; 62(1):70-6. PubMed ID: 16154330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
    Dhumal RS; Shimpi SL; Paradkar AR
    Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.